{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:55:03Z","timestamp":1780527303103,"version":"3.54.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary pulmonary enteric adenocarcinoma (PEAC) is a rare invasive adenocarcinoma clinically similar to metastatic colorectal adenocarcinoma (MCRC). Although many studies have addressed the differential diagnosis of PEAC, few have described the treatment of PEAC, especially using immunotherapy. This report describes a 61-year-old man who presented initially with pain in the ribs. Pathological analysis of biopsy samples shows malignant tumors of the right pleura, and next-generation sequencing of 26 genes showed a <jats:italic>KRAS<\/jats:italic> gene mutation. Positron emission tomography-computed tomography (PET-CT) found no evidence of gastrointestinal malignancy. Due to multiple metastases, the patient could not undergo radical surgery. The patient was treated with a combination chemotherapy regimen of paclitaxel plus carboplatin, along with sindilizumab immunotherapy, but, after one cycle of treatment, the tumor showed a hyperprogressive state. The patient is still being monitored regularly. These findings indicate that chemotherapy combined with immunotherapy may be ineffective in the treatment of primary PEAC with positive driver genes.<\/jats:p>","DOI":"10.3389\/fonc.2022.799549","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:38:18Z","timestamp":1646638698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Chun-Hong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911015)68:8<1754::aid-cncr2820680818>3.0.co;2-e","article-title":"Primary Pulmonary Adenocarcinoma With Enteric Differentiation","volume":"68","author":"Tsao","year":"1991","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-19-4171","article-title":"Pulmonary Enteric Adenocarcinoma: A Literature Review","volume":"12","author":"Li","year":"2020","journal-title":"J Thorac Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201107-042ST","article-title":"American Thoracic Society. International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary","volume":"8","author":"Travis","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101123","article-title":"Pulmonary Enteric Adenocarcinoma","volume":"14","author":"Gong","year":"2021","journal-title":"Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPB04XWICTFERL","article-title":"Primary Pulmonary Adenocarcinoma With Intestinal Differentiation Mimicking Metastatic Colorectal Carcinoma: Case Report and Review of Literature","volume":"131","author":"Li","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2864","article-title":"Clinicopathological Observation of Primary Lung Enteric Adenocarcinoma and Its Response to Chemotherapy: A Case Report and Review of the Literature","volume":"11","author":"Lin","year":"2016","journal-title":"Exp Ther Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000266","article-title":"Clinical Analysis of 23 Patients Pathologically Diagnosed With Primary and Secondary Pulmonary Enteric Adenocarcinoma","author":"Gu","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12967-018-1449-z","article-title":"Distinctive Features of Immunostaining and Mutational Load in Primary Pulmonary Enteric Adenocarcinoma: Implications for Differential Diagnosis and Immunotherapy","volume":"16","author":"Chen","year":"2018","journal-title":"J Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.lungcan.2019.10.005","article-title":"Next Generation Sequencing of Lung Adenocarcinoma Subtypes With Intestinal Differentiation Reveals Distinct Molecular Signatures Associated With Histomorphology and Therapeutic Options","volume":"138","author":"Jurmeister","year":"2019","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression During Anti-PD-1\/PD-L1 Therapy in Patients With Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"28","author":"Saada-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive Disease: Recognizing a Novel Pattern to Improve Patient Management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors After Immunotherapy: Analysis of Genomic Alterations Associated With Accelerated Growth Rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-Fc\/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1\/PD-L1 Blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2226","article-title":"Capturing Hyperprogressive Disease With Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria","volume":"26","author":"Matos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12885-020-07206-4","article-title":"Clinical Characteristics of Hyperprogressive Disease in NSCLC After Treatment With Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3332\/ecancer.2015.559","article-title":"Enteric-Type Adenocarcinoma of the Lung Harbouring a Novel KRAS Q22K Mutation With Concomitant KRAS Polysomy: A Case Report","volume":"9","author":"Metro","year":"2015","journal-title":"Ecancermedicalscience"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.799549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:38:20Z","timestamp":1646638700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.799549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":16,"alternative-id":["10.3389\/fonc.2022.799549"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.799549","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"799549"}}